2024年6月14日 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.